These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26846845)

  • 1. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
    Pagani E; Ruffini F; Antonini Cappellini GC; Scoppola A; Fortes C; Marchetti P; Graziani G; D'Atri S; Lacal PM
    Int J Oncol; 2016 Apr; 48(4):1581-9. PubMed ID: 26846845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.
    Ruffini F; Graziani G; Levati L; Tentori L; D'Atri S; Lacal PM
    Int J Cancer; 2015 Mar; 136(6):E545-58. PubMed ID: 25284767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.
    Ruffini F; D'Atri S; Lacal PM
    Int J Oncol; 2013 Jul; 43(1):297-306. PubMed ID: 23685409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.
    Ruffini F; Levati L; Graziani G; Caporali S; Atzori MG; D'Atri S; Lacal PM
    Oncotarget; 2017 Sep; 8(40):66833-66848. PubMed ID: 28977999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
    Mäenpää N; Tiainen L; Hämäläinen M; Luukkaala T; Tanner M; Lahdenperä O; Vihinen P; Karihtala P; Kellokumpu-Lehtinen PL; Moilanen E; Jukkola A
    BMC Cancer; 2024 Mar; 24(1):331. PubMed ID: 38468231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
    Levati L; Ruffini F; Muzi A; Umezawa K; Graziani G; D'Atri S; Lacal PM
    Int J Oncol; 2011 Jan; 38(1):241-7. PubMed ID: 21109946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
    Lacal PM; Ruffini F; Pagani E; D'Atri S
    Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
    Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
    Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1.
    Colotti G; Failla CM; Lacal PM; Ungarelli M; Ruffini F; Di Micco P; Orecchia A; Morea V
    FEBS J; 2022 Jan; 289(1):183-198. PubMed ID: 34252269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF.
    Liu W; Parikh AA; Stoeltzing O; Fan F; McCarty MF; Wey J; Hicklin DJ; Ellis LM
    Cytokine; 2005 Dec; 32(5):206-12. PubMed ID: 16289960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
    Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
    J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential.
    Ceci C; Ruffini F; Falconi M; Atzori MG; Falzon A; Lozzi F; Iacovelli F; D'Atri S; Graziani G; Lacal PM
    Biomed Pharmacother; 2024 Jul; 176():116766. PubMed ID: 38788599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.
    Jayasinghe C; Simiantonaki N; Kirkpatrick CJ
    BMC Cancer; 2015 Mar; 15():104. PubMed ID: 25880726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
    Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
    J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
    Straume O; Akslen LA
    Angiogenesis; 2003; 6(4):295-301. PubMed ID: 15166498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition.
    Pérez-Lozano ML; Sandoval P; Rynne-Vidal A; Aguilera A; Jiménez-Heffernan JA; Albar-Vizcaíno P; Majano PL; Sánchez-Tomero JA; Selgas R; López-Cabrera M
    PLoS One; 2013; 8(4):e60776. PubMed ID: 23585849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.